Abstract: The present invention provides vectors and/or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and/or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.

Abstract: The present invention relates to the fields of veterinary medicine and virology and provides a vaccine against leishmaniasis. In particular, the invention relates to an isolated polynucleotide comprising (i) a first expression cassette comprising a nucleic acid encoding heat shock protein (hsp) 65, and (ii) a second expression cassette comprising a nucleic acid encoding LACK (Leishmania homologue of receptors for activated C kinase). In other embodiments, the invention relates to a DNA plasmid comprising the polynucleotide, a DNA vaccine for use in the treatment of leishmaniasis, and a method of immunizing a subject against an infection with leishmaniasis.

Abstract: A device for administering a fluid is provided, with a cylinder (16, 116) which has an open dispensing end (17), a piston (36) which is displaceable between a front end position and a rear end position in the cylinder (16, 116) and is connected to a piston rod (35, 135) that protrudes along a first direction beyond a rear end of the cylinder (16, 116) opposite the open dispensing end (17) and is guided in a receiving block (10), a nonreturn valve (18) closing the open dispensing end (17), and a tensioning device (S) which is connected to the piston rod (35, 135) and is arranged in the receiving block (10), wherein the tensioning device (S), when the piston (36) is in the front end position, can move the piston rod (35, 135) in a tensioning operation along the first direction until the piston (36) is in the rear end position in order thereby to fill the cylinder (16, 116) with the fluid to be administered and in order to pretension the piston rod (35, 135) toward the open dispensing end (17), and wherein th

Abstract: A process for chiral separation of ethyl 3-amino-1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate (VI) from the racemic mixture of ethyl 3-amino-1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate and ethyl 3-amino-1-[(3S,4R)-4-cyanotetrahydropyran-3-yl]pyrazole-4-carboxylate (V).

Abstract: The present invention pertains to the use of conjugated deoxynivalenol (DON) in a method to protect an animal against DON induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, liver damage, stomach ulcers and/or kidney damage as a result of the ingestion of DON.

Abstract: The present invention is directed to an immunogenic composition comprising an antigen of Equine Herpes Virus type 1 (EHV-1) and an antigen of Equine Herpes Virus type 4 (EHV-4). The immunogenic composition reduces viremia and other clinical reactions in horses infected with EHV-1 when compared to non-treated horses but also when compared to EHV-1 vaccinated horses.

Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.

Abstract: The present invention is based on the discovery of new and advantageous properties of a class of known polymeric emulsifiers. The emulsifier class was found to be resistant to degradation by crude bacterial antigen preparations, which degradation caused emulsion instability when using prior art emulsifiers. This allows the formulation of safe, stable, and effective vaccines based on these emulsions of oil and water comprising such bacterial antigens. The polymeric emulsifier is a block copolymer having a general formula A-B-A in which component B is the divalent residue of a water-soluble polyalkylene glycol and component A is the residue of an oil-soluble complex monocarboxylic acid. Preferred emulsifier is a PEG-30-di-(polyhydroxystearate).

Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.

Abstract: The present invention relates to vaccination against animal pathogens using alphavirus-replicon RNA particles and oil adjuvants. To a vaccine, and a kit of parts comprising the replicon particles and the oil adjuvant. Also to methods and uses of making and using the vaccine and the components of the kit.

Abstract: The present invention relates to the field of vaccinology, more specifically of veterinary vaccinology. In particular, the invention relates to an adjuvant composition comprising an emulsion of water, tocopherol or a pharmaceutically acceptable ester thereof, and a polyethoxyethylene cetostearyl ether as an emulsifier. Said adjuvant composition can be used for formulating a vaccine, particularly an emulsion vaccine, comprising a bacterial, parasitic, or viral antigen. The resulting vaccine composition can be used in a method of protecting a human or animal target against infection and/or disease caused by a pathogen, particularly caused by a bacterium, parasite or virus. The invention further relates to methods for the manufacture of such adjuvant compositions and for the manufacture of such vaccine composition.

Abstract: The present invention relates to liquid vaccine composition comprising a live virus and a natural deep-eutectic solvent (NADES) as the carrier. The carrier additionally comprises an additive selected from methionine and (hydroxy) ectoine. The additive is able to reduce the loss of virus titre over time, upon storage in a NADES-based liquid vaccine composition having up to 50% w/w of water. Such compositions are less viscous which is favourable for the manufacture of the carrier, and the formulation and use of the liquid vaccine.

Abstract: An injectable pharmaceutical composition for treating a bacterial infection in an animal comprising an effective amount of a compound of Formula (I) or salt thereof, and a pharmaceutically acceptable carrier, wherein the injectable pharmaceutical composition is both efficacious and safe.

Abstract: The present invention discloses compounds that are useful in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

Abstract: A method of preparing a compound of Formula (I) or salt thereof, with reduced carboxylic acid by-product production.

Abstract: The current invention provides the use compounds of Formula (I) which are JAK inhibitors, and as such for the treatment of JAK-1 mediated diseases such as atopic—and allergic dermatitis in young animals.

Abstract: Disclosed is a novel pharmaceutical composition for the treatment of car infections in an animal with a single dose administration comprising a gentamicin antibiotic, a posaconazole antifungal and a mometasone anti-inflammatory.

Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.

Abstract: The present invention relates to a liquid composition of live Mollicutes bacteria and a stabiliser, whereby the stabiliser is a natural deep-eutectic solvent (NADES). In this liquid composition the live Mollicutes are stabilised without need for freezing or freeze-drying. This allows various advantageous uses in diagnostics and medicine, specifically as a liquid vaccine for use against infection or disease caused by Mollicutes bacteria, for human- or non-human animals.

Abstract: A device for administering a fluid is provided, with a cylinder (16, 116) which has an open dispensing end (17), a piston (36) which is displaceable between a front and rear end position in the cylinder (16, 116) and is connected to a piston rod (35) that protrudes along a first direction beyond a rear end of the cylinder (16, 116) opposite the open dispensing end (17) and is guided in a receiving block (10), a nonreturn valve (18) closing the open dispensing end (17), and a tensioning device (S) which is connected to the piston rod (35, 135) and is arranged in the receiving block (10). The tensioning device (S) has a ramp (52) which is rotatable by means of a motor (12) and has a ramp track (53) extending along a helical line, wherein the ramp track (53) ascends from a first plateau along a region of inclination (S1, S2) to a second plateau and descends from the second plateau to the first plateau via a transition flank (46).